BlueNord ASA (OSL:BNOR)
Norway · Delayed Price · Currency is NOK 488.00
+3.00 (0.62%)
Aug 5, 2025, 11:36 AM CET
Revance Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 794.3 | 702.3 | 795 | 966.9 | 565.3 | 566 | Upgrade | |
Revenue Growth (YoY) | 9.85% | -11.66% | -17.78% | 71.04% | -0.12% | 69.97% | Upgrade |
Cost of Revenue | 342.2 | 310.4 | 340.1 | 323.4 | 292.7 | 295 | Upgrade |
Gross Profit | 452.1 | 391.9 | 454.9 | 643.5 | 272.6 | 271 | Upgrade |
Selling, General & Admin | 12.6 | 13.9 | 16.6 | 11.5 | 10.7 | 11 | Upgrade |
Other Operating Expenses | 69.5 | 70.7 | 64.8 | 68.1 | 46.6 | 45 | Upgrade |
Operating Expenses | 280.7 | 225.9 | 185.4 | 213.8 | 170.3 | 251 | Upgrade |
Operating Income | 171.4 | 166 | 269.5 | 429.7 | 102.3 | 20 | Upgrade |
Interest Expense | -158.5 | -133.6 | -19.5 | -24.9 | -89 | -86 | Upgrade |
Interest & Investment Income | 13.7 | 15.8 | 17.8 | 4 | - | 2 | Upgrade |
Currency Exchange Gain (Loss) | -2.6 | 4.7 | -8.6 | 2.5 | 4.6 | -24 | Upgrade |
Other Non Operating Income (Expenses) | 10.4 | -40.9 | -16.7 | -136 | -13 | 74 | Upgrade |
EBT Excluding Unusual Items | 34.4 | 12 | 242.5 | 275.3 | 4.9 | -14 | Upgrade |
Merger & Restructuring Charges | -1.8 | -1.8 | - | - | - | - | Upgrade |
Other Unusual Items | -58 | -22.3 | 1 | 33.7 | - | -4 | Upgrade |
Pretax Income | -25.4 | -12.1 | 243.5 | 309 | 4.9 | -18 | Upgrade |
Income Tax Expense | 2.3 | 58.7 | 133.7 | 317.8 | 58.1 | -35 | Upgrade |
Earnings From Continuing Operations | -27.7 | -70.8 | 109.8 | -8.8 | -53.2 | 17 | Upgrade |
Net Income | -27.7 | -70.8 | 109.8 | -8.8 | -53.2 | 17 | Upgrade |
Net Income to Common | -27.7 | -70.8 | 109.8 | -8.8 | -53.2 | 17 | Upgrade |
Net Income Growth | - | - | - | - | - | -92.09% | Upgrade |
Shares Outstanding (Basic) | 26 | 26 | 26 | 25 | 24 | 24 | Upgrade |
Shares Outstanding (Diluted) | 26 | 26 | 26 | 25 | 24 | 35 | Upgrade |
Shares Change (YoY) | 1.45% | 1.06% | 4.16% | 3.71% | -31.32% | 102.50% | Upgrade |
EPS (Basic) | -1.05 | -2.69 | 4.22 | -0.35 | -2.21 | 0.70 | Upgrade |
EPS (Diluted) | -1.08 | -2.70 | 4.20 | -0.40 | -2.21 | 0.37 | Upgrade |
EPS Growth | - | - | - | - | - | -97.00% | Upgrade |
Free Cash Flow | 162.2 | 72.2 | -61.2 | 317.3 | -178.3 | 112 | Upgrade |
Free Cash Flow Per Share | 6.12 | 2.74 | -2.35 | 12.69 | -7.39 | 3.19 | Upgrade |
Gross Margin | 56.92% | 55.80% | 57.22% | 66.55% | 48.22% | 47.88% | Upgrade |
Operating Margin | 21.58% | 23.64% | 33.90% | 44.44% | 18.10% | 3.53% | Upgrade |
Profit Margin | -3.49% | -10.08% | 13.81% | -0.91% | -9.41% | 3.00% | Upgrade |
Free Cash Flow Margin | 20.42% | 10.28% | -7.70% | 32.82% | -31.54% | 19.79% | Upgrade |
EBITDA | 408.7 | 355.7 | 421.4 | 611.2 | 249.5 | 249 | Upgrade |
EBITDA Margin | 51.45% | 50.65% | 53.01% | 63.21% | 44.14% | 43.99% | Upgrade |
D&A For EBITDA | 237.3 | 189.7 | 151.9 | 181.5 | 147.2 | 229 | Upgrade |
EBIT | 171.4 | 166 | 269.5 | 429.7 | 102.3 | 20 | Upgrade |
EBIT Margin | 21.58% | 23.64% | 33.90% | 44.44% | 18.10% | 3.53% | Upgrade |
Effective Tax Rate | - | - | 54.91% | 102.85% | 1185.71% | - | Upgrade |
Revenue as Reported | - | - | - | - | 565.3 | 566 | Upgrade |
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.